Bevacizumab (VEGFA) - Research Grid Biosimilar
Gecertificeerd

Bevacizumab (VEGFA) - Research Grid Biosimilar

Catalog #: 10-068
Maat: 0.1 mg

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100
Technische Documentatie

Technische Specificaties

Background

Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

Immunogen

Humanized / VEGFA [Homo sapiens]

Clonality

• Recombinant Monoclonal

Conjugation

Unconjugated

Type

Primary Antibodies, Biosimilars

Source

CHO cells

Field of Research

Cancer

Purification

>95%

Concentration

Batch dependent

Buffer

PBS buffer pH7.5

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

Fragment

IgG1-kappa

NCBI Organism

Homo sapiens

Other Product Names

12-IgG1, F (ab) -12 IgG1, Fab-12 IgG1, rhuMAb-VEGF, VEGFA, VEGFA

Beschrijving

Bevacizumab (VEGFA) - Research Grid Biosimilar Beschikbaar in 0.1 mg. Bestel eenvoudig online met snelle levering.

Specificaties

ProductnaamBevacizumab (VEGFA) - Research Grid Biosimilar
Categorie
Beschikbare grootte0.1 mg
Catalogusnummer10-068